

# Thermo Scientific EliA SARS-CoV-2-Sp1 IgG Test

An assay designed to support global efforts to understand the COVID-19 pandemic

Quantitative measurement of IgG antibodies to the SARS-CoV-2 spike (S) S1 protein, with all of the benefits of Thermo Scientific™ EliA™ test technology on the fully automated Thermo Scientific™ Phadia™ 250 laboratory system.

## Quantitative IgG results can be useful for many applications



Understanding the variation in antibody levels in COVID-19 patients<sup>1</sup>




Tracking antibody trends in patients over time<sup>1</sup>




Screening convalescent plasma and understanding potential immunity and vaccine response<sup>1,2</sup>

## The value of S-protein diagnostics and IgG detection



### IgG antibodies

- Antibodies of this isotype persist post-symptom onset and are likely important for long-term immunity.<sup>3</sup>



### S protein

- The major surface protein that SARS-CoV-2 uses to bind to a receptor and invade cells.<sup>4</sup>
- The major target of many vaccine approaches, with the goal of eliciting neutralizing antibodies.<sup>5</sup>



### RBD

- The major target of neutralizing antibodies.<sup>6-9</sup>
- A unique region with less similarity to other coronaviruses, which helps eliminate cross-reactivity and improve assay specificity.<sup>10</sup>



Results you can trust: Exceptional clinical performance in diverse samples\*

- **100% sensitivity eight days after a positive PCR test** observed in a study of 65 subjects who presented with moderate-to-severe COVID-19 symptoms.
- **99.7% specificity** in 330 ethnically diverse samples from age- and gender-matched pre-pandemic blood donors.
- **No cross-reactivity** was detected when using the EliA SARS-CoV-2-Sp1 IgG Test to test 747 specimens from people with infectious or autoimmune diseases ranging from influenza and HIV to other human coronaviruses.

\* Demonstrated in experiments for IVD CE Marking.

Seamless integration onto the Phadia 250 laboratory system

- Full automation, including dilutions.
- Minimal hands-on system prep time and long walkaway times.
  - On-board reagent storage.
  - Ready-to-use reagents.
- A shared 28-day stable calibration curve with over 20 other EliA IgG tests, including all EliA tests for Connective Tissues Diseases as well as EliA CCP.



Product	Article No.	Kit Size	Description
<b>Thermo Scientific EliA SARS-CoV-2 Sp1 IgG Test</b>	14-6663-01	4 carriers (16 wells each); sufficient for 64 determinations	Fluoroenzymeimmunoassay (FEIA) intended for quantitative detection of IgG antibodies to SARS-CoV-2 spike 1 in human serum and plasma (Li-heparin, EDTA)
<b>EliA CoV Positive Control C1 250</b>	83-1185-01	6 single-use vials (0.3 mL each); sufficient for 2 determinations per vial	Control containing IgG antibodies to SARS-CoV-2 spike 1 protein

## References

1. Hanson KE, et al. Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Serological Testing. Infectious Diseases Society of America. 2020. Epub 2020/08/18.
2. Lerner AM, et al. The COVID-19 Serology Studies Workshop: Recommendations and Challenges. Immunity. 2020. Epub 2020/07/02. doi: 10.1016/j.immuni.2020.06.012.
3. Bohn, M, et al. Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence. Clin Chem Lab Med. 2020; <https://doi.org/10.1515/cclm-2020-0722>
4. Pillay TS. Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein. J Clin Pathol. 2020;73(7):366-9. doi: 10.1136/jclinpath-2020-206658.
5. Thanh Le T, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19(5):305-6. doi: 10.1038/d41573-020-00073-5.
6. Wan, J., et al. Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection. Cell Rep 2020;32(3): 107918.
7. Wu, Y., et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2." Science 2020;368(6496): 1274-1278.
8. Cao, Y., et al. Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells. Cell 2020;182(1): 73-84.e16
9. Rogers, T. F., et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020; 10.1126/science.abc7520.
10. Chia, W. N., et al. Serological differentiation between COVID-19 and SARS infections. Emerg Microbes Infect. 2020;9(1): 1497-1505.